 CAMBRIDGE, Mass., Oct. 28, 2021 GLOBE NEWSWIRE -- Rubius Therapeutics, Inc. Nasdaq: RUBY, a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell TherapeuticsTM for the treatment of cancer and autoimmune diseases, today announced plans to report third quarter financial results on Monday, November 8, 2021, after market close. 